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OBJECTIVEdThe relationship between impaired fasting glucose (IFG) and risk of cardiovas-
cular disease (CVD) or ischemic heart disease (IHD) varies widely according to sex and ethnicity.
We evaluated the relationship between IFG and CVD or IHD among Korean men and women.
RESEARCHDESIGNANDMETHODSdA total of 408,022 individuals who underwent
voluntary private health examinations in 17 centers in South Korea were followed for 10 years.
Data regarding CVD or IHD events were obtained from the Korean National Health Insurance
database. IFG was categorized as grade 1 (fasting glucose 100–109 mg/dL) or grade 2 (110–125
mg/dL).
RESULTSdIncidence rates of CVD (per 100,000 person-years) were 2,203 for diabetes. Age-
adjusted hazard ratios (HRs) for CVDwere 1.17 (95%CI 1.13–1.20) for grade 1 IFG, 1.30 (1.24–
1.35) for grade 2 IFG, and 1.81 (1.75–1.86) for diabetes. The increased risk for women was
similar to that of men. Age-adjusted HRs for IHD and ischemic stroke were also signiﬁcantly
increased for men and women with IFG and diabetes. After multivariate adjustment of conven-
tional risk factors (hypertension, dyslipidemia, smoking, obesity, and family history of CVD), the
overall risk of CVD was greatly attenuated in all categories. However, the HRs for IHD and
ischemic stroke remained signiﬁcantly increased in men for grade 2 IFG but not in women.
CONCLUSIONSdIn Korea, grade 2 IFG is associated with increased risk of IHD and ische-
mic stroke, independent of other conventional risk factors, in men but not in women.
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I t is well-established that type 2 diabe-tes is associated with amarked increasein the risk of cardiovascular disease
(CVD) and ischemic heart disease (IHD)
(1–4). Studies suggest that atherosclerosis
develops before the onset of clinical dia-
betes (5,6). Supporting this possibility,
many studies have reported that impaired
glucose tolerance (IGT) is associated with
increased cardiovascular morbidity and
mortality (7,8). However, the association
between impaired fasting glucose (IFG)
and risk of CVD and/or IHD remains un-
clear (7–18). Although some studies have
reported that IFG was associated with a
greater risk of IHD/CVD in women than
inmen (17,19), others have reported sim-
ilar risks for men and women (18).
There has also been considerable de-
bate regarding the threshold glucose level
associated with increased CVD risk. In
2003, the American Diabetes Association
(ADA) lowered the fasting plasma glucose
(FPG) cutoff point for IFG from 110 to
100 mg/dL (20). Some studies have re-
ported that FPG levels of 110–125 mg/
dL were associated with signiﬁcantly
higher rates CVD morbidity or mortality,
but that FPG levels of 100–109 mg/dL
were not (12,13). However, other inves-
tigators reported that the relationship be-
tween CVD risk and fasting glucose was
continuous or J-shaped rather than
showing a threshold effect at high glucose
levels (18,21). However, most studies
were based mainly on Caucasian popula-
tions, and only a few studies have assessed
the relationship between IFG and CVD
risk in Asian populations (13,14,18). Fur-
thermore, most of these studies analyzed
IHD and stroke together as CVD, whereas
few studies have analyzed IHD, ischemic
stroke, and hemorrhagic stroke separately
(14,22).
The primary purpose of this study
was to determine whether IFG is associ-
ated with increased risk of CVD, IHD,
and/or stroke in the Korean population.
We also assessed potential sex differences,
which have been shown in some previous
studies (17,19). Finally, we evaluated
whether the CVD risk associated with
fasting serum glucose (FSG) levels of
100–109 mg/dL is similar to the risk as-
sociated with FSG levels of 110–125 mg/
dL (the 1997 ADA deﬁnition of IFG).
RESEARCH DESIGN AND
METHODSdParticipants for this
study were drawn from a pool of
408,022 individuals (247,615 men and
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160,407 women) who had voluntarily
undergone private health examinations
in 17 centers located in one capital and six
provinces in South Korea from 1996–
2004. The National Health Screening Pro-
gram in Korea supports all men and
women over the age of 20 years to receive
basic health screening for hypertension,
diabetes, hypercholesterolemia, protein-
uria, pulmonary tuberculosis, and breast
and cervical cancer (for women) biannu-
ally. However, many Korean companies
provide more extensive private health ex-
amination program for their employees
annually. Considerable proportions (var-
ies from 40–80% depending on each
health screening center) of private health
examinations are for employees and their
spouses. Remaining proportions are for
individuals who voluntarily want to get
more extensive health screening beyond
the National Health Screening Program.
We have labeled this study as the
Korean Heart Study. Individuals with pre-
vious history of coronary heart disease
(CHD), cerebrovascular accident, or malig-
nancy (n = 23,227) were excluded. Finally,
data for 384,795 participants were col-
lected for a mean follow-up of 10 years
(median 9.4 years). This study was ap-
proved by the institutional review board
of each participating center including
Asan Medical Center.
Data collection
Of 80 health promotion centers in South
Korea, around half routinely store their
records electronically; of these, 17 agreed
to provide data. Medical history and
baseline laboratory data obtained during
the health checkups were collected from
the 17 participating centers. Data ﬁles
were collected from centers that main-
tained electronic databases, and manual
data coding was performed by trained
personnel for data collected from centers
that kept paper medical records.
Questionnaire. Questionnaires included
items on smoking habits (current smoker,
nonsmoker, or ex-smoker), alcohol con-
sumption (yes/no), regular exercise (yes/
no), education level, family history of CHD
or cerebrovascular accident, and medica-
tion history.
Laboratory data standardization. Total
cholesterol, triglyceride, HDL cholesterol,
and FSG levels were measured at each
center using autoanalyzers. LDL choles-
terol was measured directly or calculated
by the Friedewald equation. In 2006, the
Korean Association of Quality Assur-
ance for Clinical Pathology conducted a
nationwide study of interlaboratory agree-
ment, and the Department of Clinical
Pathology at Asan Medical Center was in
charge of the analysis. After receiving writ-
ten permission, we reviewed interlabora-
tory correlations for the participating
centers. The interlaboratory correlation
coefﬁcients for all measured variables
exceeded 0.95.
Outcome ascertainment
Outcome variables were morbidity from:
1) IHD alone (ICD-10 codes I20–I25); 2)
stroke alone (ICD-10 codes I60–I69); and
3) total CVD. The latter category included
hypertensive disease (ICD-10 codes I10–
I15), IHD (ICD-10 codes I20–I25), hem-
orrhagic stroke (ICD-10 codes I60–I62),
ischemic stroke (ICD-10 code I63), other
stroke (ICD-10 codes I64–I69), other dis-
ease likely related to atherosclerotic CVD
(ICD-10 codes I44–I51), sudden death
(ICD-10 code R96), and other vascular
disease (ICD-10 codes I70–I74). For in-
dividuals with more than one event, we
used just the ﬁrst event in our analysis.
The follow-up period lasted 14 years,
from January 1997 to December 2010.
Outcomes were ascertained from di-
agnosis on hospital discharge summaries
and from the cause of death on death
certiﬁcates. Computerized searches of
death certiﬁcate data from the National
Statistical Ofﬁce in Korea were performed
for each of the Korean National Health
Insurance Corporation enrollees. For
morbidity, which is deﬁned exclusively
by hospital discharge diagnosis, follow-
up is likely to approach 100%, because all
bills with discharge diagnosis are sub-
mitted to the National Health Insurance
Corporation.
We conducted the IHD event valida-
tion study in collaboration with the Ko-
rean Heart Association through the
formation of the Event Validation Com-
mittee (July 2008 to May 2009). For the
participants who provided written per-
mission for use of their personal informa-
tion, 673 CHD events were conﬁrmed
with individual hospital medical re-
cords that 73% of myocardial infarction
were valid (23). Another previous study
reported that 83% of stroke diagnoses
were valid (24).
Disease deﬁnitions (deﬁnition
of dysglycemia)
Obesity was deﬁned by the World Health
Organization Asian reference as BMI.25
kg/m2. Hypertension was deﬁned as sys-
tolic blood pressure $140 mmHg,
diastolic blood pressure $90 mmHg, or
use of antihypertensive medication. Dia-
betes was deﬁned as FSG $126 mg/dL,
use of glucose-lowering medication, or
past medical history of diabetes. IFG
was deﬁned using the 2003 ADA cri-
teria (20) and classiﬁed as grade 1 (FSG
100–109 mg/dL) or grade 2 (FSG 110–
125 mg/dL).
Statistical analysis
Baseline characteristics of each group
were compared by ANOVA or x2 tests.
Incidence rates were expressed as cases
per 100,000 person-years. The Cox pro-
portional hazard model was used to cal-
culate hazard ratios (HRs) of developing
CVD. Models were initially age-adjusted
and then adjusted for multiple covari-
ates for each end point. The proportional
hazards assumption in the Cox model
was checked graphically and with the
Schoenfeld residual test. All proportional-
ity assumptions were generally appropri-
ate. Statistical analyses were conducted
using SAS software version 9.12 (SAS in-
stitute, Cary, NC). All tests were two-sided,
and P , 0.05 was considered signiﬁcant.
RESULTSdTable 1 shows the baseline
characteristics of participants without
CVD at baseline according to glycemic
status. Incidence rates of CVD (per
100,000 person-years) were 1,084 for
grade 1 IFG, 1,416 for grade 2 IFG, and
2,203 for type 2 diabetes (Table 2). Age-
adjusted HRs for CVD were signiﬁcantly
increased for participants with grade 1
IFG (1.17 [95% CI 1.13–1.20]), grade 2
IFG (1.30 [1.24–1.35]), and type 2 dia-
betes (1.81 [1.75–1.86]). The HRs of
CVD for men were similar to those for
women (grade 1 IFG, 1.13 [1.09–1.18]
vs. 1.21 [1.15–1.27]; grade 2 IFG, 1.32
[1.25–1.39] vs. 1.24 [1.15–1.34]; and
type 2 diabetes, 1.80 [1.73–1.87] vs.
1.83 [1.74–1.93], respectively). In the
total study population, the increased
CVD risk associated with dysglycemia
persisted after adjusting for multiple
conventional risk factors such as systolic
blood pressure, antihypertensive medi-
cations, LDL and HDL cholesterol levels,
smoking status, BMI, and family history
of CVD (grade 1 IFG, 1.02 [0.99–1.05];
grade 2 IFG, 1.05 [1.01–1.10]; and type
2 diabetes, 1.49 [1.45–1.54]). However,
when we analyzed men and women sep-
arately, the multivariable-adjusted HR
for CVD remained signiﬁcantly increased
in men but not in women with grade 2
IFG.
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The age-adjusted HR for IHD also in-
creased signiﬁcantly according to glycemic
status (grade 1 IFG, 1.17 [1.11–1.24];
grade 2 IFG, 1.30 [1.21–1.40]; and type
2 diabetes, 1.95 [1.85–2.05]) (Table 2).
After adjusting for other conventional
risk factors, the increased HRs remained
signiﬁcant (grade 1 IFG, 1.06 [1.01–
1.12]); grade 2 IFG, 1.11 [1.03–1.20];
and type 2 diabetes, 1.70 [1.61–1.79]).
When we analyzed men and women
separately, the association was signiﬁcant
in men with grade 2 IFG, but the multi-
variable-adjusted HRs for grade 1 and
grade 2 IFG were not signiﬁcant in
women.
The relationship between dysglycemia
and risk of ischemic stroke was similar to
that of IHD (Table 2). Age-adjusted HRs
were signiﬁcantly increased for all three
dysglycemic groups, but the HR for grade
1 IFG was not signiﬁcant after adjusting
for multiple risk factors. When we ana-
lyzed men and women separately, these
associations were similar between men
and women, but the multivariate-adjusted
HRwas signiﬁcant for grade 2 IFG inmen.
In contrast, the risk of hemorrhagic stroke
was not increased in men or women with
IFG.
To control for the effect of hyperten-
sion, the major CVD risk factor most
commonly associated with IFG, we sep-
arately analyzed incidence rates and HRs
of IHD and ischemic stroke in prediabetic
participants with or without hypertension
(Table 3). The increased risk of IHD asso-
ciated with IFG remained signiﬁcant in-
dependent of hypertension in both men
and women. However, the risk of ische-
mic stroke was signiﬁcantly increased in
men, but not in women, with IFGwithout
hypertension.
To examine the association between
FSG andCVD in detail, the fasting glucose
range was further divided into smaller
categories (10-mg/dL intervals). In the
total study population, multivariate-
adjusted HR for IHD was signiﬁcantly in-
creased in categories of FSG.100 mg/dL,
but those for CVD and ischemic stroke
were increased only in FSG .120 mg/dL
(Fig. 1 and Supplementary Table 1).
When we analyzed men and women sep-
arately, the risks of CVD, IHD, and ische-
mic stroke were increased signiﬁcantly
above the FSG levels of 110, 100, and
126 mg/dL, respectively, in men (Fig. 1
and Supplementary Table 2), and 120,
126, and 120 mg/dL, respectively, in
women (Fig. 1 and Supplementary Table
3) after additional adjustment for meno-
pause status.
CONCLUSIONSdIn this large Ko-
rean cohort, the 2003 ADA deﬁnition of
IFG (FSG 100–125 mg/dL) is associated
with an increased risk of CVD, although
the risk was lower for grade 1 IFG (FSG
100–109 mg/dL) than for grade 2 IFG
(FSG 110–125 mg/dL). Although diabe-
tes and prediabetes are frequently associ-
ated with other cardiovascular risk factors
(e.g., hypertension, obesity, smoking,
and dyslipidemia), the association be-
tween IFG and CVD, IHD, and ischemic
stroke remained signiﬁcant after adjust-
ing for those potential confounders.
Our ﬁndings are in general agreement
with previous studies in other popula-
tions (18,19,25,26), which showed that
IFG is associated with CVD risk indepen-
dent of other CVD risk factors. Although
there have been a number of studies on
this issue, most studies were performed in
Europe and North America, and adjust-
ments for confounding factors were het-
erogeneous among studies. In a recent
meta-analysis of 102 prospective studies
involving ;700,000 participants of mul-
tiethnic background (26), only ,4%
(;23,000) of the participants were Asians
(all from Japan). In addition, fasting glu-
cose level was available only in ;40%
(;288,000 of 699,000) of the partici-
pants.
In Korean population, a large study
utilizing data of ;650,000 individuals
was also conducted previously (22), but
the participants were limited tomale pub-
lic servants aged 30–64 years. Our study
could analyze the relationship between
Table 1dBaseline characteristics of subjects without CVD (N = 384,795)
FSG categories
Normoglycemia
(,100 mg/dL)
Prediabetes Diabetes ($126 mg/dL
or medication) P value100–109 mg/dL 110–125 mg/dL
No. of subjects (%) 289,511 (75.2) 49,921 (13.0) 17,975 (4.7) 27,388 (7.1)
Sex (male) (%) 58.7 68.1 71.3 69.1 ,0.0001
Age (years) 44.7 6 9.7 47.7 6 9.9 50.1 6 9.7 52.0 6 9.6 ,0.0001
Smoking (%)
Current smoker 33.6 34.7 34.9 34.8
Ex-smoker 14.0 19.5 21.9 21.3 ,0.0001
Alcohol (%) 61.9 67.8 69.4 65.5 ,0.0001
Exercise (%) 56.1 55.5 55.0 49.4 ,0.0001
CVD family history 7.4 7.2 6.8 7.2 0.0158
BMI (kg/m2) 23.4 6 2.9 24.4 6 2.9 25.0 6 3.0 24.6 6 3.0 ,0.0001
Obesity (BMI$25 kg/m2, %) 28.6 41.7 49.7 43.0 ,0.0001
Systolic BP (mmHg) 119.3 6 16.8 126.1 6 17.8 130.6 6 18.8 129.2 6 19.5 ,0.0001
Diastolic BP (mmHg) 75.3 6 11.5 79.1 6 11.8 81.6 6 12.1 80.1 6 12.0 ,0.0001
Hypertension (%) 21.7 33.4 43.6 45.0 ,0.0001
Total cholesterol (mg/dL) 191.1 6 34.5 201.0 6 36.1 207.0 6 37.8 204.7 6 39.7 ,0.0001
HDL cholesterol (mg/dL) 51.4 6 11.9 50.0 6 11.8 49.2 6 11.7 48.3 6 11.6 ,0.0001
LDL cholesterol (mg/dL) 115.3 6 31.9 122.2 6 33.7 125.3 6 35.6 123.7 6 35.8 ,0.0001
Triglyceride (mg/dL) 132.6 6 86.9 157.6 6 103.6 179.4 6 121.7 185.8 6 141.4 ,0.0001
Fasting glucose (mg/dL) 87.0 6 7.5 103.6 6 2.8 115.5 6 4.3 146.4 6 52.9 ,0.0001
Data are means 6 SD unless otherwise indicated. BP, blood pressure.
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Table 2dIncidence rates (1/100,000 person-years), HRs, and 95% CIs of CVDs by different traits of dysglycemia
FSG categories
Normoglycemia
(,100 mg/dL)
Prediabetes Diabetes ($126 mg/dL
or on medication)100–109 mg/dL 110–125 mg/dL
CVD
Total
Person-years 2,750,034 471,013 166,657 247,025
Cases (n) 20,463 5,107 2,360 5,443
Incidence rates 744 1,084 1,416 2,203
Age-adjusted HR 1.0 1.17 (1.13–1.20) 1.30 (1.24–1.35) 1.81 (1.75–1.86)
MV-adjusted HR* 1.0 1.02 (0.99–1.05) 1.05 (1.01–1.10) 1.49 (1.45–1.54)
Men
Person-years 1,586,798 319,255 118,161 169,987
Cases (n) 11,658 3,209 1,611 3,615
Incidence rates 735 1,005 1,363 2,127
Age-adjusted HR 1.0 1.13 (1.09–1.18) 1.32 (1.25–1.39) 1.80 (1.73–1.87)
MV-adjusted HR* 1.0 1.01 (0.97–1.05) 1.10 (1.05–1.17) 1.52 (1.46–1.58)
Women
Person-years 1,163,237 151,758 48,496 77,038
Cases (n) 8,805 1,898 749 1,828
Incidence rates 757 1,251 1,544 2,373
Age-adjusted HR 1.0 1.21 (1.15–1.27) 1.24 (1.15–1.34) 1.83 (1.74–1.93)
MV-adjusted HR* 1.0 1.04 (0.99–1.09) 0.96 (0.89–1.04) 1.45 (1.38–1.53)
IHD
Total
Person-years 2,813,023 486,835 174,127 263,667
Cases (n) 6,650 1,712 801 2,018
Incidence rates 236 352 460 765
Age-adjusted HR 1.0 1.17 (1.11–1.24) 1.30 (1.21–1.40) 1.95 (1.85–2.05)
MV-adjusted HR* 1.0 1.06 (1.01–1.12) 1.11 (1.03–1.20) 1.70 (1.61–1.79)
Men
Person-years 1,618,678 328,417 122,948 108,209
Cases (n) 4,277 1,186 604 1,456
Incidence rates 264 361 491 1,346
Age-adjusted HR 1.0 1.14 (1.07–1.22) 1.34 (1.23–1.46) 1.93 (1.82–2.05)
MV-adjusted HR* 1.0 1.06 (0.99–1.13) 1.18 (1.08–1.29) 1.71 (1.61–1.82)
Women
Person-years 1,194,344 158,418 51,179 83,458
Cases (n) 2,373 526 197 562
Incidence rates 199 332 385 673
Age-adjusted HR 1.0 1.23 (1.11–1.35) 1.19 (1.03–1.38) 1.98 (1.81–2.18)
MV-adjusted HR* 1.0 1.09 (0.99–1.20) 0.97 (0.84–1.13) 1.67 (1.52–1.84)
Ischemic stroke
Total
Person-years 2,834,609 492,472 176,439 269,404
Cases (n) 2,457 648 347 954
Incidence rates 87 132 197 354
Age-adjusted HR 1.0 1.13 (1.04–1.24) 1.38 (1.23–1.55) 2.14 (1.98–2.31)
MV-adjusted HR* 1.0 1.02 (0.93–1.11) 1.18 (1.05–1.33) 1.85 (1.71–2.00)
Men
Person-years 1,633,131 332,544 124,836 184,560
Cases (n) 1,402 410 238 628
Incidence rates 86 123 191 340
Age-adjusted HR 1.0 1.12 (1.01–1.25) 1.41 (1.23–1.62) 2.10 (1.91–2.32)
MV-adjusted HR* 1.0 1.03 (0.92–1.16) 1.24 (1.08–1.43) 1.87 (1.70–2.06)
Women
Person-years 1,201,478 159,928 51,603 84,844
Cases (n) 1,055 238 109 326
Continued on p. 332
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FSG and CVD in both men and women,
and we included more aged people (up to
74 years) with broad range of socioeco-
nomic status enrolled on a nationwide
scale from17 centers. In addition,we could
further adjust the data for important poten-
tial confounders such as LDL- and HDL-
cholesterol levels and antihypertensive
medications. Therefore, our study could
provide additional information on the re-
lationship between fasting glucose level
and cardiovascular risk in a large number
of Asian population. Furthermore, thor-
ough health checkup data at baseline al-
lowed us more accurate adjustments for
other cardiovascular risk factors.
A study conducted in China (14) also
reported that IFG (FSG 100–125 mg/dL)
was signiﬁcantly associated with an in-
creased 10-year risk of CVD, CHD, and
ischemic stroke, although they did not
separately analyze FSG levels of 100–
109 mg/dL (designated as grade 1 IFG
in our study). However, hyperglycemia
without any other metabolic syndrome
component was not associated with in-
creased risk of CVD, suggesting that the
increased CVD risk in individuals with
IFG or diabetes was largely driven by
the coexistence of multiple metabolic dis-
orders rather than hyperglycemia per se.
However, only a small percentage of par-
ticipants in their study exhibited IFG
without other metabolic syndrome com-
ponents. In our results, HRs were sub-
stantially lower after adjusting for
multiple cardiovascular risk factors, but
remained signiﬁcant. Considerable evi-
dence has shown that hyperglycemia in-
duces inﬂammation, oxidative stress,
endothelial dysfunction (4), and ﬁbrino-
lytic and thrombotic processes that could
destabilize an atherosclerotic plaque,
leading to eventual thrombosis and clini-
cal CHD (12).
There has been considerable debate
regarding whether the 2003 ADA deﬁni-
tion of IFG (FSG 100–125 mg/dL) pre-
dicts the risk of CVD as well as the 1997
ADA deﬁnition of IFG (FSG 110–125
mg/dL). A study conducted in Taiwan
(13) reported that the 1997 deﬁnition of
IFG was associated with a signiﬁcant in-
crease in mortality related to CVD and/or
diabetes, but that the 2003 deﬁnition of
IFG did not have predictive value for
CVD or diabetes mortality. However, this
Taiwanese study did not report the rela-
tionship between IFG and incidence of
CVD. In a study of postmenopausal
women in the U.S. (12), IFG according to
the 1997 deﬁnition was associated with
an increased risk for any CHD event, but
IFG according to the 2003 deﬁnition was
not associated with increased risk. How-
ever, the study included only postmeno-
pausal women with established CHD, and
the sample size was small; therefore, it is
difﬁcult to generalize their results. In con-
trast, studies in China (14) and the U.S.
(25) showed that IFG deﬁned as FSG 100–
125 mg/dL was associated with increased
risk of CHD. In the Asia Paciﬁc Cohort
Studies (18), a positive log-linear associa-
tion was reported between FSG and the
risk of total stroke and IHD. Continuous
positive associations were observed down
to at least 4.9 mmol/L (88 mg/dL), with-
out evidence of a threshold level. A meta-
analysis of previous studies (19) indicated
that FPG showed a possible threshold ef-
fect at ;100 mg/dL (5.6 mmol/L). Al-
though we did not analyze for a speciﬁc
threshold level, our results support the
lower 2003 IFG cutoff point as a predictor
of increased IHD risk.
In our study, the increased risk for
IHD associated with IFG persisted after
adjusting for other conventional risk fac-
tors in men but not in women. In con-
trast, the Framingham Heart Study (17)
reported that hyperglycemia was associ-
ated with a greater CVD risk in women
Table 2dContinued
FSG categories
Normoglycemia
(,100 mg/dL)
Prediabetes Diabetes ($126 mg/dL
or on medication)100–109 mg/dL 110–125 mg/dL
Incidence rates 88 149 211 384
Age-adjusted HR 1.0 1.14 (0.99–1.31) 1.31 (1.07–1.59) 2.21 (1.95–2.51)
MV-adjusted HR* 1.0 1.00 (0.87–1.16) 1.07 (0.88–1.31) 1.82 (1.59–2.07)
Hemorrhagic stroke
Total
Person-years 2,841,964 494,557 177,633 273,004
Cases (n) 1,241 306 135 293
Incidence rates 44 62 76 107
Age-adjusted HR 1.0 1.15 (1.01–1.30) 1.21 (1.01–1.45) 1.53 (1.35–1.75)
MV-adjusted HR* 1.0 1.05 (0.93–1.20) 1.05 (0.88–1.27) 1.34 (1.17–1.53)
Men
Person-years 1,637,434 333,840 125,659 186,811
Cases (n) 685 192 99 205
Incidence rates 42 58 79 110
Age-adjusted HR 1.0 1.16 (0.98–1.36) 1.36 (1.10–1.68) 1.67 (1.42–1.95)
MV-adjusted HR* 1.0 1.05 (0.89–1.23) 1.17 (0.94–1.45) 1.45 (1.23–1.72)
Women
Person-years 1,204,530 160,717 51,974 86,193
Cases (n) 556 114 36 88
Incidence rates 46 71 69 102
Age-adjusted HR 1.0 1.14 (0.93–1.40) 0.94 (0.67–1.32) 1.31 (1.05–1.65)
MV-adjusted HR* 1.0 1.06 (0.86–1.30) 0.82 (0.59–1.16) 1.14 (0.90–1.44)
MV, multivariate. *Covariates: age, systolic blood pressure, antihypertensivemedication, LDL cholesterol, HDL cholesterol, current smoking, BMI, and family history
of CVD.
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than in men. The meta-analysis (19) also
reported that the relative risk for CVDwas
greater in cohorts that included women
than in cohorts of men. However, few
studies have examined this relationship
in cohorts of women only. Although
most Asian studies (13,14) did not ana-
lyze men and women separately, the
Asian Paciﬁc Cohort Study (18) showed
that fasting glucose in prediabetes and di-
abetes was an important determinant of
CVD, without a signiﬁcant difference be-
tween men and women. It is unclear that
whether these discrepancies are due to
ethnic differences or to differences in
risk factor management between popula-
tions.
Although diabetes is strongly associ-
ated with increased risk for stroke (27,28),
less is known about the risk associated
with prediabetic states. In previous cross-
sectional (29) and longitudinal studies
(12), IGT or IFG was not associated with
risk of stroke. However, many previous
studies (12,17,18) did not perform sepa-
rate analyses for ischemic and hemorrhagic
strokes. Our study showed that IFG was
associated with increased risk for ischemic
stroke but not hemorrhagic stroke, which is
consistent with results of a longitudinal
study conducted in China (14). However,
the association between IFG and risk of is-
chemic stroke appearsweak comparedwith
the association between IFG and IHD, as
increased risk of ischemic stroke was seen
only in men with grade 2 IFG (FSG 110–
125 mg/dL) after multivariate adjustment.
Our study has several limitations that
must be acknowledged. First, results of
oral glucose tolerance testing (OGTT)
were not available; therefore the 1997
and 2003 IFG deﬁnitions could not be
Table 3dIncidence rates (1/100,000 person-years), HRs, and 95% CIs of IHD and ischemic stroke of prediabetes (fasting glucose
100–125 mg/dL) with or without hypertension (N = 357,407)
Normoglycemia Prediabetes
Without hypertension With hypertension Without hypertension With hypertension
IHD
Total
Person-years 2,206,350 603,679 423,847 236,418
Cases (n) 4,005 2,636 1,233 1,276
Incidence rates 182 437 291 540
Age-adjusted HR 1.0 1.60 (1.52–1.68) 1.23 (1.16–1.31) 1.70 (1.59–1.81)
MV-adjusted HR* 1.0 1.48 (1.41–1.56) 1.14 (1.07–1.22) 1.51 (1.41–1.62)
Men
Person-years 1,237,881 379,741 291,251 159,766
Cases (n) 2,626 1,645 889 897
Incidence rates 212 433 305 561
Age-adjusted HR 1.0 1.52 (1.42–1.61) 1.18 (1.09–1.27) 1.68 (1.55–1.82)
MV-adjusted HR* 1.0 1.45 (1.36–1.54) 1.11 (1.03–1.20) 1.56 (1.44–1.69)
Women
Person-years 968,469 223,938 132,595 76,652
Cases (n) 1,379 991 344 379
Incidence rates 142 443 259 494
Age-adjusted HR 1.0 1.74 (1.60–1.90) 1.35 (1.20–1.52) 1.70 (1.51–1.91)
MV-adjusted HR* 1.0 1.58 (1.45–1.73) 1.22 (1.08–1.38) 1.46 (1.29–1.65)
Ischemic stroke
Total
Person-years 2,220,269 611,294 428,163 240,025
Cases (n) 1,283 1,173 388 606
Incidence rates 58 192 91 252
Age-adjusted HR 1.0 1.88 (1.73–2.04) 1.14 (1.02–1.28) 2.07 (1.87–2.29)
MV-adjusted HR* 1.0 1.85 (1.70–2.01) 1.10 (0.98–1.23) 2.00 (1.80–2.21)
Men
Person-years 1,247,413 384,624 294,400 162,606
Cases (n) 738 663 273 374
Incidence rates 59 172 93 230
Age-adjusted HR 1.0 1.88 (1.69–2.09) 1.19 (1.04–1.37) 2.05 (1.80–2.32)
MV-adjusted HR* 1.0 1.91 (1.71–2.13) 1.17 (1.02–1.35) 2.07 (1.81–2.36)
Women
Person-years 972,856 226,670 133,763 77,419
Cases (n) 545 510 115 232
Incidence rates 56 225 86 300
Age-adjusted HR 1.0 1.86 (1.64–2.11) 1.03 (0.84–1.26) 2.09 (1.78–2.46)
MV-adjusted HR* 1.0 1.77 (1.56–2.02) 0.96 (0.78–1.18) 1.91 (1.62–2.25)
MV, multivariate. *Covariates: age, LDL cholesterol, HDL cholesterol, current smoking, BMI, and family history of CVD.
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compared with IGT for prediction of
CVD. Further, this lack of OGTT results
may have lead to the inclusion of partic-
ipants with undiagnosed diabetes in the
IFG group. However, OGTT is more
complicated and expensive to perform
than FSGmeasurement (30), and the cur-
rent ADA guidelines do not recommend
the routine use of OGTT (31). Second, we
could not exclude participants who devel-
oped incident diabetes before CVD events
from IFG groups, because we used only
baseline FSG levels. However, most other
studies (13,14,18,25) also used only
baseline glucose values, except one study
(17) that excluded incident diabetes.
Third, our cohort was not based on a gen-
eral population sample that could repre-
sent the Korean population. However, the
large number of participants from 19 cen-
ters located throughout the country may
alleviate potential selection bias. Consid-
ering that we often encounter individuals
who are found to have IFG during rou-
tine health examinations, our results are
applicable to clinical and public health
practice. Fourth, the outcome deﬁnition
was based on hospital admissions only.
Although it was more accurate than
outpatient-based diagnosis, there were
possibilities of underestimation for the out-
comes. Finally, although many important
clinical and laboratory variables were ad-
justed for the risk analysis in this study,
several relevant factors such as use of lipid-
lowering drugs could not be adjusted prop-
erly because of incomplete data at baseline.
In conclusion, our study showed that
IFG, deﬁned as FPG levels of 100–125
mg/dL, is associated with increased risk
of CVD (including IHD and ischemic
stroke) in the Korean population. This as-
sociation is independent of other conven-
tional risk factors in men but not in
women. Further studies are needed to
identify subgroups with IFG for whom
prevention efforts in reducing cardiovas-
cular events are cost-effective.
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